Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  AVEO Pharmaceuticals, Inc.    AVEO

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

AVEO Pharmaceuticals, Inc. : DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders of AVEO Pharmaceuticals, Inc. of Upcoming Deadline

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/25/2013 | 11:25pm CEST

Rigrodsky & Long, P.A.:

  • Do you, or did you, own shares of AVEO Pharmaceuticals, Inc. (NASDAQ GS: AVEO)?
  • Did you purchase your shares before January 3, 2012, or between January 3, 2012 and May 1, 2013, inclusive?
  • Did you lose money in your investment in AVEO Pharmaceuticals, Inc.?
  • Do you want to discuss your rights?

Rigrodsky & Long, P.A., including former Special Assistant United States Attorney, Timothy J. MacFall, reminds shareholders of AVEO Pharmaceuticals, Inc. ("AVEO" or the "Company") (NASDAQ GS: AVEO) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.

A complaint was filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities that purchased the common stock of AVEO between January 3, 2012 and May 1, 2013, inclusive (the "Class Period"), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the "Complaint"). If you wish to serve as lead plaintiff, you must move the Court no later than July 8, 2013.

If you purchased shares of AVEO during the Class Period, or purchased shares prior to the Class Period and still hold AVEO, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, NY at (888) 969-4242, by e-mail to [email protected], or at: http://www.rigrodskylong.com/investigations/aveo-pharmaceuticals-inc-aveo.

A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

While Rigrodsky & Long, P.A. did not file the Complaint in this matter, the firm, with offices in Wilmington, Delaware and Garden City, New York, regularly litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

Rigrodsky & Long, P.A.
Timothy J. MacFall, Esquire
Peter Allocco
888-969-4242
516-683-3516
Fax: 302-654-7530
[email protected]
http://www.rigrodskylong.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AVEO PHARMACEUTICALS, INC.
10:40p AVEO PHARMACEUTICALS, INC. (NASDAQ : AVEO) Files An 8-K Departure of Directors o..
10:36p AVEO PHARMACEUTICALS INC : Change in Directors or Principal Officers, Amendments..
03:10p AVEO ONCOLOGY : Announces $14M in Aggregate Gross Proceeds from Hercules Credit ..
06/23 NETWORKNEWSBREAKS – AVEO ONCOL : AVEO) Shares Skyrocket on CHMP’s Re..
06/23 AVEO PHARMACEUTICALS, INC. (NASDAQ : AVEO) Files An 8-K Other Events
06/23 AVEO PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (form..
06/23 AVEO ONCOLOGY : Announces Positive CHMP Opinion for Tivozanib as a Treatment of ..
06/20 AVEO ONCOLOGY : Announces Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cel..
06/08 NETWORKNEWSBREAKS – AVEO ONCOL : AVEO) Phase 1/2 TiNivo Trial Advances to ..
06/08 AVEO ONCOLOGY : Announces Phase 1/2 TiNivo Trial of Tivozanib and Opdivo® (nivol..
More news
Sector news : Bio Therapeutic Drugs
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
11:31a Aveo Comeback Highlights A Transatlantic Split
10:30a 3 THINGS IN BIOTECH YOU SHOULD LEARN : June 27, 2017
09:13a PREMARKET LOSERS AS OF 9 : 05 am
06/26 Midday Gainers / Losers
06/26 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
Advertisement
Financials ($)
Sales 2017 7,08 M
EBIT 2017 -37,6 M
Net income 2017 -41,2 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 30,4x
Capi. / Sales 2018 19,3x
Capitalization 215 M
More Financials
Chart AVEO PHARMACEUTICALS, INC.
Duration : Period :
AVEO Pharmaceuticals, Inc. Technical Analysis Chart | AVEO | US0535881090 | 4-Traders
Full-screen chart
Technical analysis trends AVEO PHARMACEUTIC...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 2,50 $
Spread / Average Target 28%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michael P. Bailey President, Chief Executive Officer & Director
Matthew D. Dallas Chief Financial Officer
Michael N. Needle Chief Medical Officer
Emile Farhan Vice President-Technical Operations
Anthony B. Evnin Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AVEO PHARMACEUTICALS, ..261.11%138
AMGEN18.78%126 856
CELGENE CORPORATION15.64%104 873
GILEAD SCIENCES-0.52%92 150
REGENERON PHARMACEUTIC..40.93%54 987
VERTEX PHARMACEUTICALS81.09%33 251
More Results